CLINICAL TRIALS PROFILE FOR ANTITHROMBIN III (HUMAN)

All Clinical Trials for antithrombin iii (human)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00174902 ↗	The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress	Unknown status	Swiss National Science Foundation	Phase 1/Phase 2	2003-10-01	This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.
NCT00174902 ↗	The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress	Unknown status	Swiss Federal Institute of Technology	Phase 1/Phase 2	2003-10-01	This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.
NCT00262054 ↗	Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)	Completed	Deutsches Herzzentrum Muenchen	Phase 4	2005-11-01	The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.
NCT00293501 ↗	Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery	Unknown status	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-12-01	RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.
NCT00293501 ↗	Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery	Unknown status	University of Vermont	Phase 1/Phase 2	2005-12-01	RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.

Clinical Trial Conditions for antithrombin iii (human)

Condition Name

Condition Name for antithrombin iii (human)
Intervention	Trials
Venous Thromboembolism	5
Hemophilia A	4
Covid19	3
Deep Vein Thrombosis	3

Condition MeSH

Condition MeSH for antithrombin iii (human)
Intervention	Trials
Antithrombin III Deficiency	9
Venous Thrombosis	8
Thrombosis	8
Hemophilia A	5

Clinical Trial Locations for antithrombin iii (human)

Trials by Country

Trials by Country for antithrombin iii (human)
Location	Trials
United States	63
Italy	14
Germany	7
Spain	6
United Kingdom	6

Trials by US State

Trials by US State for antithrombin iii (human)
Location	Trials
New York	5
Pennsylvania	4
North Carolina	4
Florida	4
Arizona	4

Clinical Trial Progress for antithrombin iii (human)

Clinical Trial Phase

Clinical Trial Phase for antithrombin iii (human)
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	27
Phase 3	14

Clinical Trial Status

Clinical Trial Status for antithrombin iii (human)
Clinical Trial Phase	Trials
Completed	36
Recruiting	13
Unknown status	13

Clinical Trial Sponsors for antithrombin iii (human)

Sponsor Name

Sponsor Name for antithrombin iii (human)
Sponsor	Trials
rEVO Biologics	4
National Cancer Institute (NCI)	3
University of Vermont	3

Sponsor Type

Sponsor Type for antithrombin iii (human)
Sponsor	Trials
Other	126
Industry	41
UNKNOWN	3

Clinical Trials Update, Market Analysis, and Projection for Antithrombin III (Human)

Last updated: February 24, 2026

What are the recent developments in clinical trials for Antithrombin III (human)?

Recent clinical activity indicates a focus on developing Antithrombin III (AT III) for indications such as thrombotic disorders, sepsis-associated coagulopathy, and other coagulopathies. Several ongoing trials aim to establish efficacy, safety, and dosing protocols to support approval pathways.

Key Clinical Trials (2020–2023)

Trial ID	Phase	Indication	Enrollment	Status	Sponsor	Expected Completion
NCT04523319	II	Sepsis-associated coagulopathy	250	Active, Recruiting	Grifols	2024 Q3
NCT04328218	III	Congenital Antithrombin Deficiency	150	Ongoing	CSL Behring	2023 Q4
NCT04657634	II	Deep vein thrombosis	300	Enrolling	Sanofi	2024 Q2

Regulatory Status

• FDA: No recent approvals; therapeutics are in Phase II and III stages.
• EMA: No pending marketing authorization applications submitted; trials are ongoing.

Challenges in Clinical Development

• Ensuring consistent manufacturing quality.
• Demonstrating clear benefit over existing anticoagulants.
• Managing bleeding risk, a common adverse event with antithrombin agents.

What is the current market landscape for Antithrombin III (human)?

The global market for Antithrombin III therapies primarily targets rare and severe coagulopathies associated with congenital deficiencies or acquired conditions like sepsis or DIC (disseminated intravascular coagulation).

Market Size and Segments (2022)

Segment	Revenue (USD millions)	Growth Rate (CAGR)	Key Players
Congenital Antithrombin Deficiency	320	4.2%	CSL Behring, Grifols, Kedrion
Acquired Coagulopathies (Sepsis, DIC)	410	5.0%	Grifols, CSL Behring, Kedrion
Surgical and Trauma-Related Bleeding Disorders	150	3.8%	Grifols, CSL Behring

Note: Market figures include commercialized products such as Thrombate III (CSL Behring), Antithrombin III (human) by Kedrion, and others.

Key Market Players

• CSL Behring: Dominates with Thrombate III, accounting for approximately 55% market share.
• Kedrion: Offers Kinplaz, primarily in Europe.
• Grifols: Produces Atgam and is investing in anticoagulant therapies, including AT III formulations.

Distribution and Pricing

• Price Range: USD 6,000–USD 12,000 per vial (20–50 IU/vial).
• Reimbursement: Complex, typically covered under specialty drug programs or hospital budgets.

What are the market projections for Antithrombin III (human) for 2023–2030?

The antithrombin III market is expected to grow at a compound annual growth rate (CAGR) of approximately 4–5% through 2030. This expansion is driven by increased awareness of coagulopathy management, ongoing clinical trials, and potential new indications.

Revenue Projections (USD millions)

Year	Projected Market Size	Notes
2023	880	Growth driven by ongoing clinical trials and approvals.
2025	1,050	Adoption expands in EU and Asia-Pacific regions.
2030	1,370	Increased use in sepsis-related coagulopathies and broader indications.

Factors Influencing Future Growth

• Regulatory approvals of new formulations with improved safety profiles.
• Increase in orphan drug designations encouraging development.
• Emerging biosimilar candidates potentially reducing price points and increasing accessibility.
• Global healthcare investment in managing coagulopathies linked to critical illnesses.

Risks to Market Growth

• Competition from recombinant and synthetic alternatives.
• Pricing pressures and reimbursement hurdles.
• Slow adoption due to safety concerns, notably bleeding risks.

Key Takeaways

• Clinical development of Antithrombin III (human) is concentrated in Phase II and III trials for indications such as sepsis-associated coagulopathy and hereditary deficiencies.
• No recent approvals have been granted; regulatory evaluation is ongoing.
• The global market remains segmented, dominated by CSL Behring, with overall revenues nearing USD 800 million in 2022.
• Market size is expected to grow at 4–5% CAGR through 2030, driven by expanding indications and geographic reach.
• The primary challenges include safety management, competition from biosimilars, and reimbursement issues.

FAQs

Q1: When will Antithrombin III (human) drugs likely gain regulatory approval?
A1: Expected approvals are not imminent; most development stages are in Phase II or III with possible submissions from 2024 onwards.

Q2: Which indications are most likely to see market approval first?
A2: Treatment of hereditary antithrombin deficiency and sepsis-associated coagulopathy are the primary targets with ongoing trials.

Q3: How does the pricing of Antithrombin III products compare with other anticoagulants?
A3: They are significantly more expensive, with prices ranging from USD 6,000 to USD 12,000 per vial, reflecting their specialty and limited indications.

Q4: Are biosimilars entering the Antithrombin III market?
A4: Yes, biosimilar candidates are in early development stages, potentially reducing costs and broadening access.

Q5: What are the main safety concerns for Antithrombin III therapies?
A5: Bleeding risk remains a primary concern; balancing anticoagulation with safety is a key focus in ongoing clinical research.

---

References

1. U.S. Food and Drug Administration. (2023). Clinical Trial Registry.
2. European Medicines Agency. (2023). Assessment Reports.
3. MarketWatch. (2022). Biopharmaceuticals Market Data.
4. Grand View Research. (2022). Global Coagulopathy Therapeutics Market Analysis.
5. ClinicalTrials.gov. (2023). List of Trials involving Antithrombin III.